After embarking on an adaptive new development project to make QUINVAXEM® a fully liquid pentavalent vaccine (DTwP-HepB-Hib) available in a compact prefilled autodisable (cPAD) injection system (Becton Dickinson’s Uniject), Janssen Vaccines made the decision to stop the development of this injection system.